Analysts estimate that Madrigal Pharmaceuticals will report an earnings per share (EPS) of $-1.99.
The announcement from Madrigal Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Past Earnings Performance
In the previous earnings release, the company beat EPS by $1.62, leading to a 0.24% drop in the share price the following trading session.
Here's a look at Madrigal Pharmaceuticals's past performance and the resulting price change:
Quarter
Q2 2025
Q1 2025
Q4 2024
Q3 2024
EPS Estimate
-3.52
-3.79
-4.12
-6.91
EPS Actual
-1.90
-3.32
-2.71
-4.92
Price Change %
0.00
-4.00
-6.00
23.00
Stock Performance
Shares of Madrigal Pharmaceuticals were trading at $418.9 as of October 31. Over the last 52-week period, shares are up 19.37%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Observations about Madrigal Pharmaceuticals
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Madrigal Pharmaceuticals.
Analysts have given Madrigal ...
